galantamine has been researched along with Disease Exacerbation in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (60.61) | 29.6817 |
| 2010's | 12 (36.36) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Honjo, Y; Ide, K; Takechi, H | 1 |
| Bauer, C; Frölich, L; Heuser, I; Joachim, LK; Kornhuber, J; Maier, W; Peters, O; Rüther, E; Wiltfang, J | 1 |
| Adorni, F; Caltagirone, C; Di Santo, SG; Musicco, M; Prinelli, F | 1 |
| Shoji, M | 1 |
| Isik, AT; Soysal, P | 1 |
| Abe, K; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Shang, J; Yamashita, T; Zhai, Y | 1 |
| Hughes, TL; Iraqi, A | 1 |
| Lane, R; Venneri, A | 1 |
| Leifer, BP | 1 |
| Gaudig, M; Guo, S; Hernandez, L; Wasiak, R | 1 |
| Léger, GC; Massoud, F | 1 |
| Atri, A | 1 |
| Stefanacci, RG | 1 |
| Aisen, PS; Cummings, J; Schneider, LS | 1 |
| DiBernardo, A; Farnum, M; Lobanov, V; Narayan, V; Novak, G; Raghavan, N; Samtani, MN; Schultz, T; Shi, Y; Verbeeck, R; Yang, E | 1 |
| Fesche, A; Frölich, L; Gertz, HJ; Heuser, I; Hüll, M; Jahn, H; Jessen, F; Kornhuber, J; Lorenz, D; Luckhaus, C; Maier, W; Möller, HJ; Pantel, J; Perneczky, R; Peters, O; Rüther, E; Schmidtke, K; Schröder, J; Teipel, S; Wellek, S | 1 |
| Caro, JJ; Garfield, FB; Getsios, D; Wimo, A; Winblad, B | 1 |
| Damaraju, CV; Kershaw, P; Peskind, ER; Raskind, MA; Truyen, L | 1 |
| Happich, M; Mühlbacher, A; Schweikert, B | 1 |
| Bhanji, NH; Gauthier, S | 1 |
| Johannsen, P | 1 |
| Dai, D; Mitnitski, A; Rockwood, K | 1 |
| Green, C | 1 |
| Neno, R | 1 |
| Barkhof, F; Fox, NC; Korf, ES; Scheltens, P; van de Pol, LA; van der Flier, WM | 1 |
| Engel, J; Hager, K; Kenklies, M; McAfoose, J; Münch, G | 1 |
| Brashear, R; Bullock, R; Erkinjuntti, T; Gauthier, S; Hammond, G; Kurz, A; Schwalen, S; Zhu, Y | 1 |
| Liao, S; Morrison, LJ | 1 |
| Coyle, J; Kershaw, P | 1 |
| Caro, G; Caro, JJ; Getsios, D; Ishak, K | 1 |
| Murray, J; Wilkinson, D | 1 |
| Sternon, J; Ventura, M | 1 |
| Robert, P | 1 |
12 review(s) available for galantamine and Disease Exacerbation
| Article | Year |
|---|---|
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Disability Evaluation; Disease Progression; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2013 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Disease Progression; Donepezil; Education, Medical, Continuing; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Peptide Fragments; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Reference Standards; Rivastigmine; tau Proteins; Tomography, Emission-Computed, Single-Photon | 2014 |
Pharmacological treatment of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Neuropsychological Tests; Piperidines | 2011 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2011 |
The costs of Alzheimer's disease and the value of effective therapies.
Topics: Age Factors; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Health Care Costs; Health Expenditures; Humans; Indans; Medicare; Medicare Part D; Memantine; Piperidines; Psychometrics; United States | 2011 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Donepezil; Drug Approval; Galantamine; Ginkgo biloba; Half-Life; History, 20th Century; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Psychotropic Drugs; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Sesquiterpenes; Vitamin B Complex; Vitamin E | 2012 |
A novel subject synchronization clinical trial design for Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; Disease Progression; Galantamine; Humans; Nootropic Agents; Research Design | 2012 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine | 2007 |
Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.
Topics: Aged; Allosteric Regulation; Allosteric Site; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Galantamine; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Receptors, Nicotinic | 2001 |
[Anticholinesterase agents in Alzheimer's disease].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Disease Progression; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Treatment Outcome | 2001 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Progression; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2002 |
7 trial(s) available for galantamine and Disease Exacerbation
| Article | Year |
|---|---|
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Topics: Aged; Alzheimer Disease; Amnesia; Cholinesterase Inhibitors; Cognition; Cognitive Dysfunction; Cohort Studies; Dementia; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Galantamine; Germany; Humans; Male; Memantine; Middle Aged; Nootropic Agents; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate | 2012 |
The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Double-Blind Method; Electrocardiography; Female; Galantamine; Humans; Long-Term Care; Male; Neuropsychological Tests; Psychiatric Status Rating Scales | 2004 |
[Cost-effectiveness of galantamine in a german context].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Galantamine; Germany; Humans; Male; Markov Chains; Mental Status Schedule; National Health Programs; Nootropic Agents; Psychometrics; Quality-Adjusted Life Years; Statistics as Topic; Survival Rate | 2005 |
Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment.
Topics: Age Factors; Aged; Alzheimer Disease; Apolipoprotein E4; Atrophy; Biomarkers; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Galantamine; Genetic Predisposition to Disease; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Fibers, Myelinated; Neuropsychological Tests; Predictive Value of Tests; Prognosis | 2007 |
Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.
Topics: Aged; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Long-Term Care; Male; Mental Status Schedule; Middle Aged; Oxidative Stress; Piperidines; Thioctic Acid | 2007 |
Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cerebrovascular Disorders; Cognition; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; Galantamine; Humans; Male; Nootropic Agents; Psychomotor Performance; Risk Assessment | 2008 |
Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Status Schedule; Treatment Outcome | 2001 |
14 other study(ies) available for galantamine and Disease Exacerbation
| Article | Year |
|---|---|
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Donepezil; Female; Galantamine; Humans; Japan; Male; Memantine; Mental Status and Dementia Tests; Retrospective Studies; Rivastigmine | 2020 |
Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial.
Topics: Activities of Daily Living; Amygdala; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction; Disease Progression; Double-Blind Method; Female; Galantamine; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Memantine; Neuroimaging; Neuropsychological Tests; Peptide Fragments; Randomized Controlled Trials as Topic; tau Proteins; Withholding Treatment | 2018 |
Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Body Mass Index; Body Weight; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Eating; Female; Follow-Up Studies; Galantamine; Geriatric Assessment; Humans; Indans; Male; Nutrition Assessment; Nutritional Status; Piperidines; Polypharmacy; Retrospective Studies; Rivastigmine | 2016 |
Strong Impact of Chronic Cerebral Hypoperfusion on Neurovascular Unit, Cerebrovascular Remodeling, and Neurovascular Trophic Coupling in Alzheimer's Disease Model Mouse.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Cerebrovascular Disorders; Disease Models, Animal; Disease Progression; Galantamine; Humans; Male; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Neuroprotective Agents; Neurovascular Coupling; Nootropic Agents; Receptors, Nicotinic | 2016 |
An unusual case of nightmares with galantamine.
Topics: Aged; Alzheimer Disease; Delayed-Action Preparations; Disease Progression; Dreams; Galantamine; Humans; Male; Neuropsychological Tests; Nootropic Agents | 2009 |
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinesterase Inhibitors; Cytoprotection; Disease Progression; Donepezil; Drug Synergism; Drug Therapy, Combination; Female; Galantamine; Humans; Image Processing, Computer-Assisted; Indans; Magnetic Resonance Imaging; Male; Nerve Fibers, Myelinated; Neural Pathways; Neuroprotective Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2009 |
Alzheimer's disease: Seeing the signs early.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Primary Health Care; Psychometrics; Rivastigmine; Time Factors | 2009 |
Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany.
Topics: Aged, 80 and over; Alzheimer Disease; Caregivers; Disease Progression; Female; Galantamine; Germany; Ginkgo biloba; Humans; Long-Term Care; Male; Models, Economic; Nootropic Agents; Severity of Illness Index | 2010 |
Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clinical Trials as Topic; Cost of Illness; Disease Progression; Drug Costs; Galantamine; Health Care Costs; Health Services Needs and Demand; Health Services Research; Humans; Institutionalization; Long-Term Care; Models, Econometric; Nootropic Agents; Probability; Sensitivity and Specificity; Sweden | 2002 |
Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies.
Topics: Aged; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Male; Mental Status Schedule; Neuropsychological Tests; Piperidines | 2005 |
Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Topics: Aged; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Cognition; Disease Progression; Europe; Female; Follow-Up Studies; Galantamine; Humans; Logistic Models; Male; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
NICE judgement leaves behind a nasty taste.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Formularies as Topic; Galantamine; Humans; Indans; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Jurisprudence; Phenylcarbamates; Piperidines; Rivastigmine; State Medicine; Time Factors; United Kingdom | 2007 |
Dementia medications in palliative care #174.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Palliative Care; Phenylcarbamates; Piperidines; Prognosis; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2008 |
Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Canada; Clinical Trials as Topic; Cost Control; Disease Progression; Female; Galantamine; Health Services Needs and Demand; Humans; Long-Term Care; Male; Models, Economic; Nootropic Agents | 2001 |